Resultats globals: 1 registres trobats en 0.02 segons.
Articles, 1 registres trobats
Articles 1 registres trobats  
1.
8 p, 1.1 MB Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis : Benefit/risk following review of trial and post-marketing data / Coles, Alasdair J. (University of Cambridge) ; Jones, Joanne L. (University of Cambridge) ; Vermersch, Patrick (Université de Lille) ; Traboulsee, Anthony (University of British Columbia) ; Bass, Ann D. (Neurology Center of San Antonio) ; Boster, Aaron (Boster Center for Multiple Sclerosis) ; Chan, Andrew (University of Bern) ; Comi, Giancarlo (Vita-Salute San Raffaele University) ; Fernández, Óscar (Hospital Regional Universitario Carlos Haya (Málaga)) ; Giovannoni, Gavin (Queen Mary University of London) ; Kubala Havrdova, Eva (Charles University) ; LaGanke, Christopher (North Central Neurology Associates) ; Montalban, Xavier (Hospital Universitari Vall d'Hebron) ; Oreja-Guevara, Celia (Universidad Complutense de Madrid) ; Piehl, Fredrik (Karolinska Institutet (Estocolm, Suècia)) ; Wiendl, Heinz (University of Münster) ; Ziemssen, Tjalf (Dresden University of Technology) ; Universitat Autònoma de Barcelona
Does preexisting or treatment-emergent autoimmunity increase the risk of subsequent autoimmune disease in individuals with relapsing-remitting multiple sclerosis (MS) after alemtuzumab? In the extended phase 2/3 trials, 34/96 (35. [...]
2022 - 10.1177/13524585211061335
Multiple sclerosis, Vol. 28 Núm. 5 (2022) , p. 842-846  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.